Abdul Mutlib, Ph.D.
Dr. Abdul Mutlib is the Chief Scientific and Strategy Officer at Frontage Laboratories, Inc. Dr. Mutlib has successfully held several executive roles including the Chief Executive Officer and the Global Head of DMPK/Preclinical Services.
Prior to joining Frontage in 2010, he held scientific and leadership roles at Wyeth and Pfizer. Earlier in his career, he held scientific positions on the drug metabolism teams at Hoechst-Roussel (now Sanofi-Aventis) and DuPont-Merck. With more than 37 years of experience in drug discovery and development, Dr. Mutlib’s interest includes: drug metabolism and analytical chemistry; application of various analytical techniques and stable isotope labeled compounds in elucidating structures of metabolites and metabolic pathways; mass spectrometry; qualitative and quantitative NMR; metabolism-mediated toxicities; reactive metabolites; phase II metabolism; drug-drug interactions; and toxicogenomics. He has published more than sixty-nine papers in peer-reviewed journals, written 3 book chapters, and holds 3 patents. He participates as a reviewer for several scientific journals.
Dr. Mutlib earned a bachelor’s degree in pharmacy and a Doctor of Philosophy degree in pharmaceutical chemistry from the University of Sydney in Australia. He completed post-doctoral fellowships from the Universities of Washington and British Columbia.
